SCHEDULE 13G/A: Forbion Entities Amend Beneficial Ownership Disclosure in Dyne Therapeutics

Multiple Forbion-affiliated investment entities have filed an amended Schedule 13G, detailing their collective beneficial ownership in Dyne Therapeutics, Inc. common stock as of March 31, 2025.

Summary

• ForDyne B.V. beneficially owns 5,400,545 shares of Dyne Therapeutics, Inc. common stock, representing 4.8% of the outstanding class.
• Forbion Capital Fund IV Cooperatief U.A. and its director, Forbion IV Management B.V., each beneficially own 4,036,476 shares, accounting for 3.6% of the outstanding common stock.
• Forbion Growth Opportunities Fund II Cooperatief U.A. and its director, Forbion Growth II Management B.V., each beneficially own 1,426,370 shares, representing 1.3% of the outstanding common stock.
• These ownership percentages are calculated based on 113,633,782 outstanding shares of Dyne Therapeutics Common Stock as of March 31, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed on May 8, 2025.
• ForDyne B.V. is identified as a joint investment vehicle wholly owned by Forbion IV COOP and Forbion II COOP, though it does not exercise voting or dispositive power over the shares held on their behalf.
• The reporting persons are making a single, joint filing, acknowledging they may be deemed to constitute a 'group' under Section 13(d)(3) of the Securities Exchange Act of 1934, but they disclaim actual group membership for other purposes.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain qualitative information to assess sentiment beyond neutrality. It's an expected regulatory filing.

Positives

• Continued significant beneficial ownership by institutional investment funds (Forbion entities) in Dyne Therapeutics, indicating ongoing investment interest.

Future Outlook

NA

Industry Context

This filing reflects the ongoing investment activities of specialized venture capital and growth equity funds (Forbion entities) in publicly traded companies like Dyne Therapeutics, Inc. Such disclosures provide transparency into significant institutional holdings within the sector.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional holdings, which can influence market perception and liquidity.

Key Dates

Keywords

Dyne Therapeutics, Forbion, Schedule 13G, Beneficial Ownership, SEC Filing, Common Stock, Institutional Investment